

Contents

Preface — V

1 General aspects — 1

- 1.1 History — 1
 - 1.1.1 From willow bark to salicylic acid — 9
 - 1.1.1.1 Antiinflammatory and analgesic effects of willow bark — 9
 - 1.1.1.2 Salicylates as the active ingredients of willow bark and other natural sources — 10
 - 1.1.1.3 Chemical synthesis of salicylic acid — 10
 - 1.1.2 Synthesis of acetylated salicylic acid (Aspirin) and first medical use — 13
 - 1.1.2.1 The invention of acetylated salicylic acid — 13
 - 1.1.2.2 Introduction of acetylsalicylic acid in the clinic — 20
 - 1.1.3 Search for pharmacological modes of aspirin action — 23
 - 1.1.3.1 Salicylates and energy metabolism of the cell — 24
 - 1.1.3.2 Inhibition of cyclooxygenases by salicylates — 25
 - 1.1.3.3 Further actions of salicylates on cell signaling — 30
 - 1.1.4 Clinical applications – a piece of history — 34
 - 1.1.4.1 Antiinflammatory/analgesic and antipyretic actions — 34
 - 1.1.4.2 Antiplatelet/antithrombotic actions and bleeding — 35
 - 1.1.4.3 Aspirin and the history of prevention of myocardial infarction and stroke — 37
 - 1.1.4.4 Aspirin and tumor prevention — 41
 - 1.1.5 Current research topics — 44
 - 1.1.5.1 Clinical research — 44
 - 1.1.5.2 Basic research — 45
- 1.2 Chemistry — 49
 - 1.2.1 Structures and chemical properties of salicylates — 50
 - 1.2.1.1 Salicylates in clinical use – chemical properties — 51
 - 1.2.1.2 Aspirin formulations — 53
 - 1.2.2 Determination of salicylates — 56
 - 1.2.2.1 General aspects — 56
 - 1.2.2.2 Methods of determination — 57

2 Pharmacology — 61

- 2.1 Pharmacokinetics — 62
 - 2.1.1 Absorption and distribution — 63
 - 2.1.1.1 Absorption and bioavailability — 63
 - 2.1.1.2 Aspirin formulations and application modes — 66
 - 2.1.1.3 Distribution and plasma levels — 71

2.1.1.4	Modifying factors —	73
2.1.2	Biotransformation and excretion —	77
2.1.2.1	Biotransformations of aspirin —	77
2.1.2.2	Biotransformations of salicylic acid —	81
2.1.2.3	Excretion of salicylates —	83
2.2	Cellular modes of action —	87
2.2.1	Inhibition of cyclooxygenases —	89
2.2.1.1	General aspects —	89
2.2.1.2	Inhibition/modulation of cyclooxygenases by aspirin —	91
2.2.1.3	The different pharmacology of aspirin and NSAIDs —	98
2.2.1.4	Further actions of salicylates on lipid mediators —	100
2.2.2	COX-independent actions of aspirin on cell function —	104
2.2.2.1	General aspects —	104
2.2.2.2	Salicylates in the plant kingdom —	105
2.2.2.3	Non-COX acetylation actions of aspirin —	106
2.2.2.4	Aspirin and nitric oxide formation —	106
2.2.2.5	Salicylates and kinases —	109
2.2.2.6	Salicylates and transcription factors —	113
2.2.3	Energy metabolism —	119
2.2.3.1	General aspects —	119
2.2.3.2	Salicylates and fatty acid β -oxidation —	121
2.2.3.3	Salicylates and uncoupling of oxidative phosphorylation —	125
2.2.3.4	Metabolic actions of salicylates and Reye's syndrome —	128
2.3	Actions on organs and tissues —	133
2.3.1	Hemostasis and thrombosis —	134
2.3.1.1	General aspects —	134
2.3.1.2	Platelets —	137
2.3.1.3	Endothelial cells —	145
2.3.1.4	Plasmatic coagulation —	150
2.3.1.5	Fibrinolysis —	150
2.3.2	Inflammation, microbial infections, pain and fever —	160
2.3.2.1	General aspects —	160
2.3.2.2	Modes of antiinflammatory actions of aspirin —	162
2.3.2.3	Modes of antimicrobial actions of aspirin —	170
2.3.2.4	Modes of analgesic actions of aspirin —	172
2.3.2.5	Modes of antipyretic actions of aspirin —	177
2.3.3	Aspirin and malignancies —	185
2.3.3.1	General aspects —	185
2.3.3.2	Pathophysiology of intestinal neoplasias —	187
2.3.3.3	Modes of aspirin action —	191
2.3.3.4	COX-related actions of aspirin —	192
2.3.3.5	Non-COX-related antitumor actions of aspirin —	196

- 3 Toxicity and drug safety — 207**
- 3.1 Systemic side effects — 208
- 3.1.1 Acute and chronic toxicity — 209
 - 3.1.1.1 General aspects — 209
 - 3.1.1.2 Pathophysiology and clinical symptoms of acute toxicity — 211
 - 3.1.1.3 Pathophysiology and clinical symptoms of chronic toxicity — 214
 - 3.1.1.4 Treatment — 215
 - 3.1.1.5 Habituation — 216
- 3.1.2 Bleeding time and bleeding risk — 221
 - 3.1.2.1 General aspects — 221
 - 3.1.2.2 Bleeding time — 221
 - 3.1.2.3 Modes of aspirin action — 225
 - 3.1.2.4 Aspirin-related bleeding in long-term prevention — 227
 - 3.1.2.5 Aspirin-related bleeding in surgery and withdrawal — 228
 - 3.1.2.6 Prevention and treatment of bleeding — 230
- 3.1.3 Safety pharmacology in particular life situations — 237
 - 3.1.3.1 General aspects — 237
 - 3.1.3.2 Pregnancy and fetal development — 237
 - 3.1.3.3 The elderly patient — 241
- 3.2 Organ toxicity — 248
 - 3.2.1 Gastrointestinal tract — 248
 - 3.2.1.1 General aspects — 248
 - 3.2.1.2 Pathophysiology of gastrointestinal (stomach) injury — 249
 - 3.2.1.3 Modes of aspirin action — 252
 - 3.2.1.4 Clinical studies — 258
 - 3.2.1.5 Aspirin and other drugs — 262
 - 3.2.2 Liver — 269
 - 3.2.2.1 General aspects — 269
 - 3.2.2.2 Pathophysiology and mode of aspirin action — 270
 - 3.2.2.3 Clinical studies — 270
 - 3.2.3 Kidney and heart failure — 273
 - 3.2.3.1 General aspects — 273
 - 3.2.3.2 Mode of aspirin action — 274
 - 3.2.3.3 Clinical studies – individuals without kidney diseases — 275
 - 3.2.3.4 Clinical studies – individuals with preexisting kidney diseases — 276
 - 3.2.3.5 Heart failure — 279
 - 3.2.4 Audiovestibular system — 284
 - 3.2.4.1 General aspects — 284
 - 3.2.4.2 Pathophysiology of aspirin-induced hearing loss — 285
 - 3.2.4.3 Clinical studies — 287
- 3.3 Hypersensitivity to aspirin and Reye's syndrome — 291

- 3.3.1 Aspirin-exacerbated respiratory disease (“aspirin-induced asthma,”
Widal syndrome) — **292**
- 3.3.1.1 History and epidemiology — **292**
- 3.3.1.2 Pathophysiology of AERD — **293**
- 3.3.1.3 Mode of aspirin action — **297**
- 3.3.1.4 Clinical studies — **299**
- 3.3.1.5 Aspirin and other drugs — **301**
- 3.3.2 Urticaria/angioedema, Stevens–Johnson syndrome and Lyell
syndrome — **306**
- 3.3.2.1 Urticaria/angioedema — **306**
- 3.3.2.2 Stevens–Johnson syndrome and Lyell syndrome — **307**
- 3.3.3 Reye’s syndrome — **309**
- 3.3.3.1 History and epidemiology — **309**
- 3.3.3.2 Clinics, laboratory and morphological findings — **311**
- 3.3.3.3 Etiology and pathogenesis — **313**
- 3.3.3.4 Clinical studies — **316**
- 3.3.3.5 Actual situation — **323**

- 4 Clinical applications of aspirin — 331**
- 4.1 Thromboembolic diseases — **337**
- 4.1.1 Coronary vascular disease — **338**
- 4.1.1.1 General aspects — **338**
- 4.1.1.2 Thrombotic risk and mode of aspirin action — **340**
- 4.1.1.3 Clinical trials – primary prevention in apparently healthy
individuals — **344**
- 4.1.1.4 Clinical trials – primary prevention in individuals with vascular risk
factors — **353**
- 4.1.1.5 Clinical trials – primary prevention in patients with diabetes — **357**
- 4.1.1.6 Clinical trials – patients with chronic coronary vascular disease — **362**
- 4.1.1.7 Clinical trials – patients with acute coronary syndrome (ACS) — **363**
- 4.1.1.8 Clinical trials – long-term secondary prevention — **367**
- 4.1.1.9 Clinical trials – coronary artery bypass graft surgery and other surgical
interventions — **373**
- 4.1.1.10 Aspirin and other drugs — **376**
- 4.1.1.11 Actual situation — **390**
- 4.1.2 Cerebrovascular diseases — **409**
- 4.1.2.1 General aspects — **409**
- 4.1.2.2 Thrombotic risk and mode of aspirin action — **411**
- 4.1.2.3 Clinical trials – primary prevention — **415**
- 4.1.2.4 Clinical trials – secondary prevention — **416**
- 4.1.2.5 Aspirin and other drugs — **424**
- 4.1.2.6 Actual situation — **435**

- 4.1.3 Peripheral arterial occlusive disease — **445**
 - 4.1.3.1 General aspects — **445**
 - 4.1.3.2 Thrombotic risk and mode of aspirin action — **447**
 - 4.1.3.3 Clinical trials: primary prevention — **449**
 - 4.1.3.4 Clinical trials: secondary prevention — **451**
 - 4.1.3.5 Clinical trials: peripheral transluminal angioplasty — **452**
 - 4.1.3.6 Aspirin and other drugs — **454**
 - 4.1.3.7 Actual situation — **457**
- 4.1.4 Venous thromboembolism — **461**
 - 4.1.4.1 General aspects — **461**
 - 4.1.4.2 Thrombotic risk and modes of aspirin action — **464**
 - 4.1.4.3 Clinical trials – primary prevention — **464**
 - 4.1.4.4 Clinical trials – secondary prevention — **471**
 - 4.1.4.5 Aspirin and other drugs – NOACs — **473**
 - 4.1.4.6 Actual situation — **474**
- 4.1.5 Pregnancy-induced hypertension (preeclampsia) and preterm delivery — **479**
 - 4.1.5.1 General aspects — **479**
 - 4.1.5.2 Vascular risk and modes of aspirin action — **481**
 - 4.1.5.3 Clinical trials — **486**
 - 4.1.5.4 Clinical trials – reasons for data variability — **488**
 - 4.1.5.5 Actual situation — **492**
- 4.1.6 Aspirin “high on treatment platelet reactivity” (HTPR, aspirin resistance) — **500**
 - 4.1.6.1 General aspects — **500**
 - 4.1.6.2 Definition and types of aspirin – HTPR — **501**
 - 4.1.6.3 Detection of aspirin HTPR — **504**
 - 4.1.6.4 Mechanisms of aspirin HTPR — **507**
 - 4.1.6.5 Clinical trials — **515**
 - 4.1.6.6 Actual situation — **519**
- 4.2 Pain, fever and inflammatory diseases — **528**
 - 4.2.1 Analgesia and antipyresis — **529**
 - 4.2.1.1 General aspects — **529**
 - 4.2.1.2 Pain, fever and mode of analgesic/antipyretic aspirin action — **530**
 - 4.2.1.3 Clinical trials — **534**
 - 4.2.1.4 Aspirin and other drugs — **538**
 - 4.2.1.5 Actual situation — **539**
 - 4.2.2 Inflammatory diseases and viral infections — **542**
 - 4.2.2.1 General aspects — **542**
 - 4.2.2.2 Rheumatoid arthritis – pathophysiology, mode of aspirin action and clinical trials — **544**

- 4.2.2.3 Osteoarthritis – pathophysiology, mode of aspirin action and clinical trials — **547**
- 4.2.2.4 Systemic inflammatory response syndrome (SIRS). Pathophysiology, mode of aspirin action and clinical trials. Sepsis and acute respiratory distress syndrome (ARDS) — **548**
- 4.2.2.5 HIV – pathophysiology, mode of aspirin action and clinical trials — **552**
- 4.2.2.6 COVID-19 and flu-like conditions: pathophysiology, modes of aspirin action and clinical trials — **555**
- 4.2.2.7 Aspirin and other drugs — **559**
- 4.2.2.8 Actual situation — **560**
- 4.2.3 Kawasaki disease — **567**
 - 4.2.3.1 General aspects — **567**
 - 4.2.3.2 Pathophysiology and mode of aspirin action — **568**
 - 4.2.3.3 Clinical trials — **569**
 - 4.2.3.4 Aspirin and other drugs — **571**
 - 4.2.3.5 Actual situation — **571**
- 4.3 Further potential clinical indications — **574**
 - 4.3.1 Colorectal tumors (adenomas, carcinomas) — **575**
 - 4.3.1.1 General aspects — **575**
 - 4.3.1.2 Epidemiology, etiology and pathogenesis — **576**
 - 4.3.1.3 Modes of aspirin action — **578**
 - 4.3.1.4 Clinical trials – primary prevention — **581**
 - 4.3.1.5 Clinical trials – secondary prevention — **587**
 - 4.3.1.6 Aspirin and other drugs — **593**
 - 4.3.1.7 Actual situation — **594**
 - 4.3.2 Alzheimer’s disease and other neurological disorders — **602**
 - 4.3.2.1 General aspects — **602**
 - 4.3.2.2 Epidemiology, etiology and pathophysiology — **602**
 - 4.3.2.3 Modes of aspirin action — **603**
 - 4.3.2.4 Clinical trials — **605**
 - 4.3.2.5 Aspirin and other drugs — **609**
 - 4.3.2.6 Actual situation — **609**

Abbreviations — 613

Acronyms of clinical trials — 617

Index — 623